A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
Price : $35 *
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox (Primary) ; Azacitidine; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 09 Dec 2016 Status changed to discontinued since only one patient has been enrolled in trial, stopped for Safety and no analysis will ever be done.
- 01 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.